Treatment and outcomes of pulmonary mucosa-associated lymphoid tissue lymphoma: A multicenter analysis of 186 patients - PubMed

6 hours ago

Pulmonary MALT lymphoma is a rare, indolent lymphoma with no standard treatment; this study analyzed 186 patients diagnosed between 2013 and 2022.
Patients were staged using a modified Ann Arbor system: 70% had stage IE/IIE disease, 30% had stage IV disease, and none had stage III disease.
Overall survival (OS) at 4 years was high across stages: 96% for stage IE, 92% for stage IIE, and 90% for stage IV, with no significant differences in OS based on first-line treatment.
Progression-free survival (PFS) was significantly worse in stage IIE and IV groups compared to stage IE (p < .001), indicating these groups may need new therapeutic approaches.
In stage IV patients, the stomach was the most common synchronous extranodal site of involvement (36%).
The study concludes that OS is favorable regardless of first-line treatment, including watchful waiting, but PFS outcomes suggest stage IIE and IV patients are candidates for therapeutic development.

Hasty Briefsbeta